Hospital Universitario Puerta Del Mar — Clinical Trial Site

72 Registered trials

27 Currently recruiting

Organisation

Hospital Universitario Puerta Del Mar

Location

Cadiz, Spain

Identifier

ORG-100028569

Address

Avenida De Ana De Viya 21, 11009, Spain

Departments

#2315:servicio de neurología
#5415 :neurologia
#724003: Neurocirugía
2746; Dermatología
3455: Servicio Dermatología
3652: Pediatría
9248: Servicio Dermatología
Cardiología
Cardiology
Departamento de aparato digestivo
Dermatology
Dermatology Medical- Surgical and Venerology
Endocrinología y Nutrición
Endocrinology & Metabolism
Endocrinology and Metabolism
Hematología
Hematology
Hospital Universitario Puerta del Mar
Internal Medicine
Medical Oncology
Microbiología
Nefrología
Nefrology
Neonatology
Nephrology
Neurología
Neurology
None
Obstetrician and Gynecologist
Oncology
Oncology Department
Oncology Service
Ophthalmology
Oral and Maxillofacial Surgery
Pediatrics
Pneumology
Servicio de digestivo
Servicio de Angiología y Cirugía vascular
Servicio de Cardiología
Servicio de Oftalmología
Surgery
UGC Cuidados Intensivos
Urology
Vascular Surgery and Angiology

Clinical trials at this site (72)

Search interface

A study comparing TAR-210 versus single agent treatment instilled directly into the bladder in people with bladder cancer with FGFR gene alt… Recruiting

2023-507684-19-00 FGFR+ Intermediate-risk Non-muscle Invasive Bladder Can 5 2024-07-24
A Study to Compare the Efficacy and Safety of Glofitamab as a Single Agent Versus Investigator’s Choice in Patients with Relapsed/Refractory… Recruiting

2023-503206-37-00 Mantle Cell Lymphoma (MCL) 5 2023-11-20
EARLY treatment with Candesartan vs Placebo in asymptomatic GENEtic carriers of Dilated Cardiomyopathy (EARLY-GENE trial) Recruiting

2023-507029-40-00 Genetic carriers of dilated cardiomyopathy causing vari 5 2022-05-09
Single antiplatelet treatment with Ticagrelor or Aspirin after Transcatheter Aortic Valve Implantation: multicenter randomized clinical tria… Recruiting

2023-509290-22-00 Severe Symptomatic Aortic Stenosis 6 2022-01-21
The ABC-HCC Trial: A Phase IIIb, randomized, multicenter, open-label trial of Atezolizumab plus Bevacizumab versus transarterial Chemoemboli… Recruiting

2024-512953-26-00 intermediate-stage hepatocellular carcinoma 5 2021-07-06
LONG-TERM FOLLOW-UP STUDY OF EARLY STAGE BREAST CANCER PATIENTS INCLUDED IN GEICAM STUDIES Recruiting

2022-502706-33-00 Patients with invasive breast cancer in early stages 6 2018-01-10
Phase 2b Clinical Study Evaluating Efficacy and Safety of TAR-200 in Combination with Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Part… Ended

2023-506146-23-00 Non-Muscle-Invasive Urothelial Carcinoma (NMIBC) of the 4 2025-11-17
A Phase 3 study to assess efficacy, safety and tolerability of remibrutinib in adult and adolescent patients with moderate to severe hidrade… Ended

2024-513282-39-00 Hidradenitis Suppurativa (HS) 5 2025-05-28
A Phase 3 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria (EMBARQ – CSU1) Ended

2024-513210-36-00 Chronic Spontaneous Urticaria 5 2025-04-04
Study to evaluate efficacy and safety of inclisiran in children aged 6 to under 12 years of age with heterozygous familial hypercholesterole… Ended

2024-514594-21-00 Heterozygous Familial Hypercholesterolemia 5 2025-03-13
A Placebo-Controlled Study of Inhaled Pirfenidone in Progressive Pulmonary Fibrosis Ended

2023-508429-29-00 Progressive Pulmonary Fibrosis 4 2024-09-26
Allogeneic Tissue Engineering (Nanostructured Artificial Human Cornea) in Patients With Corneal Trophic Ulcers in Advanced Stages, Refractor… Ended

2024-515481-13-00 Corneal trophic ulcers refractory to conventional treat 7 2024-07-05
A 26-Week, Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Evaluate the Efficacy, Safety, and Tolerability of Axatilimab… Ended

2022-502954-15-00 Idiopathic pulmonary fibrosis 4 2024-06-21
Effect of Tranexamic Acid Oral Solution 5% in patients treated with direct oral anticoagulants or vitamin K antagonists and undergoing a sin… Ended

2023-503719-13-00 Prevention of clinically relevant bleeding events in pa 5 2024-05-06
A study to compare the study treatment darolutamide in combination with androgen deprivation therapy (ADT) to placebo in combination with AD… Ended

2022-501343-33-00 Biochemically recurrent prostate cancer 5 2023-10-18
A phase 3 study to Evaluate the Efficacy and Safety of HLX10 or placebo in Combination With Chemotherapy and Radiotherapy in Patients With L… Ended

2024-515047-31-00 Patients with Limited-Stage Small Cell Lung Cancer (LS- 5 2023-08-28
Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab or TAR-200 … Ended

2023-507187-39-00 High-Risk Non-muscle-invasive Bladder Cancer 5 2023-03-23
AMANTADINE AND TRANSCRANIAL MAGNETIC TRANSCRANIAL MAGNETIC STIMULATION FOR FATIGUE IN MULTIPLE SCLEROSIS: A PHASE III, CONTROLLED, RANDOMISE… Ended

2024-516732-97-00 multiple sclerosis (MS) 5 2022-11-28
Phase II study to evaluate diarrhoea discontinuations at 3 cycles in patients with early-stage HER2 positive, hormone receptor positive brea… Ended

2024-514630-21-00 HER2 positive (HER2+), Hormone Receptor positive (HR+) 4 2022-08-11
Efficacy and safety of remibrutinib compared to teriflunomide in participants with relapsing multiple sclerosis, followed by long term treat… Ended

2023-509345-12-00 Multiple Sclerosis 5 2022-06-22
Randomized clinical trial assessing the value of Beta-Blockers and Antiplatelet Agents in patients with Spontaneous Coronary Artery Dissecti… Ended

2024-516039-28-00 Spontaneous Coronary Artery Dissection. 6 2021-09-28
A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (M… Ended

2023-507188-21-00 Muscle-Invasive Urothelial Carcinoma (MIBC) of the Blad 5 2021-04-20
A Phase 3 Trial of Epcoritamab vs Investigator’s Choice Chemotherapy in R/R DLBCL Ended

2023-504830-23-00 B-cell Lymphoma 5 2020-12-16
A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared with Ocrelizumab in Adult Patients with Primary Progressive Multiple Sc… Ended

2022-502611-10-00 Primary Progressive Multiple Sclerosis (PPMS) 5 2020-11-24